CB2 / CNR2 Cancer Research Results

CB2 / CNR2, Cannabinoid receptor type 2: Click to Expand ⟱
Source:
Type:

CB2 / CNR2 : Druggable immune-enriched cannabinoid receptor involved in microglia, inflammation, immune-cell signaling, pain, neuroprotection, and tumor-immune regulation.

-when a product binds selectively to the CB2 receptors(modulates up) and not the CB1 receptor, it non-psychoactive and therapeutically appealing.
-activation of the CB2 receptor can suppress pro-inflammatory cytokines production, helping to create an anti-tumor immune environment

Field Suggested Entry
Target CB2 / CNR2
Full Name Cannabinoid receptor type 2
Target Class G-protein-coupled receptor; Gi/o-coupled cannabinoid receptor
Primary Biology Immune modulation, microglial activation, inflammatory signaling, cytokine regulation, leukocyte behavior, pain/inflammation signaling
Cancer Relevance Medium and context-dependent: may suppress inflammation or tumorigenesis in some settings, but may also support immune suppression or tumor progression depending on tumor type and immune context
AD Relevance Medium-high: microglial CB2 activation is a promising neuroinflammation strategy, with encouraging preclinical evidence in AD models but limited clinical validation
Therapeutic Direction Usually selective CB2 agonism/modulation for neuroinflammation and inflammatory disease; cancer direction is tumor-context-dependent
Key Product Links β-caryophyllene, PEA, CBD/cannabinoid-system modulators, endocannabinoids, omega-3-derived lipid mediators


Scientific Papers found: Click to Expand⟱
6512- BCP,    Beta-Caryophyllene Exhibits Anti-Proliferative Effects through Apoptosis Induction and Cell Cycle Modulation in Multiple Myeloma Cells
- in-vitro, MM, NA
CB2 / CNR2↑, BAX↑, Bcl-2↓, Casp3↑, TumCP↓, Apoptosis↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, TumCCA↑, Inflam↓, chemoPv↑, neuroP↑, *BioAv↝, CB2 / CNR2↑, tumCV↓,
6503- BCP,    The Potential Therapeutic Role of Beta-Caryophyllene as a Chemosensitizer and an Inhibitor of Angiogenesis in Cancer
- Review, Var, NA
ChemoSen↑, angioG↓, TumCI↓, TumMeta↓, ROS↑, *ROS↓, chemoP↑, CB2 / CNR2↑, Inflam↓, AntiTum↑, *BioAv↑, *BBB↑, Apoptosis↑, TumCP↑, TumCCA↑, RadioS↑, DNArepair↓, ROS↑, STAT3↓, *BioEnh↑, Pain↓, AntiBio↓, ROS↑, Dose↝, NF-kB↓, MAPK↓, TNF-α↓, IL1β↓, IL6↓, cl‑PARP↑, Casp↑, BAX↑, Bcl-2↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP2↓, p‑p38↓, p‑ERK↓, EPR↑, P-gp/ABCB1↓, MRP1/ABCC1↓, *NRF2↑, *antiOx↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 3,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 1,   MAPK↓, 1,   p‑p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNArepair↓, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑ERK↓, 1,   STAT3↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   TumCI↓, 1,   TumCP↓, 1,   TumCP↑, 1,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EPR↑, 1,   VEGF↓, 1,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CB2 / CNR2↑, 3,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 1,   MRP1/ABCC1↓, 1,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   neuroP↑, 1,   Pain↓, 1,  
Total Targets: 44

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   NRF2↑, 1,   ROS↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,   BioEnh↑, 1,  
Total Targets: 7

Scientific Paper Hit Count for: CB2 / CNR2, Cannabinoid receptor type 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1500  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page